The Phase 2 clinical trial results of a COVID-19 vaccine developed by Taiwan-based Medigen Vaccine Biologics Corp. generated good data, experts have said, but they cautioned there was still no way to know how effectively it will protect people against getting the disease.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Society
- Society
Taiwan issues land warning for Tropical Storm Danas
07/05/2025 09:38 PM - Culture
Hot air balloon festival kicks off in Taitung, stopped until Monday
07/05/2025 07:13 PM - Society
Airline, ferry services affected by Tropical Storm Danas
07/05/2025 07:05 PM - Business
Hon Hai reports new high for June sales in growing AI era
07/05/2025 05:18 PM